China Tianrui Group Cement Company Limited (HKG:1252)

Ligand Pharmaceuticals Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	915.09	125.81	601.72	1,183	1,230
Short-Term Investments	-	1,049	386.08	1,128	1,182
Trading Asset Securities	6.88	13.09	38.9	9.69	2.41
Cash & Short-Term Investments	921.97	1,188	1,027	2,320	2,415
Cash Growth	-22.39%	15.70%	-55.75%	-3.90%	30.57%
Accounts Receivable	131.47	4,702	3,267	3,449	3,918
Other Receivables	20,633	500.48	323.32	327.47	281.04
Receivables	21,764	5,203	3,591	3,777	4,199
Inventory	892.93	15,789	7,678	3,407	3,437
Prepaid Expenses	-	28.9	31.37	35.03	89.54
Restricted Cash	2,305	5,118	4,547	4,370	3,543
Other Current Assets	-	-	-	3,017	2,298
Total Current Assets	25,884	27,327	16,874	16,926	15,982
Property, Plant & Equipment	8,723	10,316	10,762	11,183	11,465
Long-Term Investments	796.27	1,004	1,087	1,111	1,076
Goodwill	10.5	84.85	284.23	300.86	294.01
Other Intangible Assets	1,578	1,569	1,499	1,379	1,408
Long-Term Deferred Tax Assets	186.42	104.81	109.61	155.77	156.84
Other Long-Term Assets	36.09	167.28	1,599	1,413	1,869
Total Assets	37,215	40,573	32,344	32,658	32,440
Accounts Payable	1,369	4,265	3,662	3,398	4,038
Accrued Expenses	-	34.97	130.67	130.86	52.03
Short-Term Debt	-	5,192	114.45	284.32	245.58
Current Portion of Long-Term Debt	11,159	7,897	6,935	6,823	7,069
Current Portion of Leases	0.9	2.18	3.58	12.13	25
Current Income Taxes Payable	592.2	270.49	302.36	331.68	525.69
Current Unearned Revenue	609	444.44	571.38	526.89	368.24
Other Current Liabilities	5,195	707.75	1,802	1,748	1,102
Total Current Liabilities	18,925	18,814	13,522	13,255	13,426
Long-Term Debt	1,683	4,623	1,397	2,349	2,678
Long-Term Leases	0.42	5.66	5.62	6.61	18.74
Long-Term Unearned Revenue	104.99	175.37	192.42	209.46	140.38
Long-Term Deferred Tax Liabilities	169.24	154.98	159.22	167.22	176.18
Other Long-Term Liabilities	356.65	1,014	477.5	602.53	1,177
Total Liabilities	21,240	24,787	15,753	16,590	17,617
Common Stock	24.18	24.18	24.18	24.18	24.18
Additional Paid-In Capital	15,713	1,067	1,067	1,067	1,067
Retained Earnings	-	12,604	13,401	12,952	11,752
Comprehensive Income & Other	-	1,772	1,823	1,840	1,851
Total Common Equity	15,737	15,466	16,315	15,884	14,694
Minority Interest	238.52	319.63	275.27	184.67	128.85
Shareholders' Equity	15,976	15,786	16,590	16,068	14,823
Total Liabilities & Equity	37,215	40,573	32,344	32,658	32,440
Total Debt	12,844	17,720	8,456	9,476	10,037
Net Cash (Debt)	-11,922	-16,532	-7,429	-7,155	-7,622
Net Cash Per Share	-4.06	-5.63	-2.53	-2.44	-2.59
Filing Date Shares Outstanding	2,938	2,938	2,938	2,938	2,938
Total Common Shares Outstanding	2,938	2,938	2,938	2,938	2,938
Working Capital	6,959	8,513	3,352	3,671	2,555
Book Value Per Share	5.36	5.26	5.55	5.41	5.00
Tangible Book Value	14,148	13,813	14,531	14,204	12,992
Tangible Book Value Per Share	4.82	4.70	4.95	4.83	4.42
Buildings	-	9,332	9,184	8,868	8,661
Machinery	-	9,274	9,190	8,830	8,626
Construction In Progress	-	368.49	335.65	434.11	278.94

Source: S&P Global Market Intelligence. Standard template. Financial Sources.